KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Retained Earnings (2016 - 2026)

Pacific Biosciences Of California has reported Retained Earnings over the past 16 years, most recently at $457000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 8.29% year-over-year to $457000.0; the TTM value through Dec 2025 reached $457000.0, up 8.29%, while the annual FY2025 figure was $457000.0, 8.29% up from the prior year.
  • Retained Earnings for Q4 2025 was $457000.0 at Pacific Biosciences Of California, up from -$2.7 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $457000.0 in Q4 2025 and troughed at -$2.7 billion in Q3 2025.
  • A 5-year average of -$1.1 billion and a median of -$1.3 billion in 2022 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: plummeted 22849650.0% in 2022 and later skyrocketed 100.02% in 2024.
  • Year by year, Retained Earnings stood at -$1.2 billion in 2021, then surged by 99.61% to -$4.8 million in 2022, then crashed by 38495.49% to -$1.8 billion in 2023, then skyrocketed by 100.02% to $422000.0 in 2024, then increased by 8.29% to $457000.0 in 2025.
  • Business Quant data shows Retained Earnings for PACB at $457000.0 in Q4 2025, -$2.7 billion in Q3 2025, and -$2.6 billion in Q2 2025.